Published in J Pharmacol Exp Ther on October 28, 2005
Small Molecules, Inhibitors of DNA-PK, Targeting DNA Repair, and Beyond. Front Pharmacol (2013) 1.05
Irinotecan and DNA-PKcs inhibitors synergize in killing of colon cancer cells. Invest New Drugs (2011) 0.91
Effects of the novel DNA dependent protein kinase inhibitor, IC486241, on the DNA damage response to doxorubicin and cisplatin in breast cancer cells. Invest New Drugs (2011) 0.85
Phase 1 trial of temozolomide plus irinotecan plus O6-benzylguanine in adults with recurrent malignant glioma. Cancer (2009) 0.81
Optimizing glioblastoma temozolomide chemotherapy employing lentiviral-based anti-MGMT shRNA technology. Mol Ther (2013) 0.76
DNA-Binding and Topoisomerase-I-Suppressing Activities of Novel Vanadium Compound Van-7. Bioinorg Chem Appl (2012) 0.75
Oncolytic adenovirus-expressed RNA interference of O(6)-methylguanine DNA methyltransferase activity may enhance the antitumor effects of temozolomide. Oncol Lett (2014) 0.75
BPR0L075, a novel synthetic indole compound with antimitotic activity in human cancer cells, exerts effective antitumoral activity in vivo. Cancer Res (2004) 1.36
Survivin - biology and potential as a therapeutic target in oncology. Onco Targets Ther (2013) 1.25
Cytotoxic triterpenes from the aerial roots of Ficus microcarpa. Phytochemistry (2005) 1.17
Targeting Hsp90 with small molecule inhibitors induces the over-expression of the anti-apoptotic molecule, survivin, in human A549, HONE-1 and HT-29 cancer cells. Mol Cancer (2010) 1.17
Aurora kinase inhibitors in preclinical and clinical testing. Expert Opin Investig Drugs (2009) 1.16
Investigations of survivin: the past, present and future. Front Biosci (Landmark Ed) (2011) 1.10
Novel phosphoinositide 3-kinase/mTOR dual inhibitor, NVP-BGT226, displays potent growth-inhibitory activity against human head and neck cancer cells in vitro and in vivo. Clin Cancer Res (2011) 1.08
Concise synthesis and structure-activity relationships of combretastatin A-4 analogues, 1-aroylindoles and 3-aroylindoles, as novel classes of potent antitubulin agents. J Med Chem (2004) 1.08
Increasing incidence of intrahepatic cholangiocarcinoma and its relationship to chronic viral hepatitis. J Natl Compr Canc Netw (2009) 1.02
Survivin counteracts the therapeutic effect of microtubule de-stabilizers by stabilizing tubulin polymers. Mol Cancer (2009) 1.01
Human DNA polymerase eta activity and translocation is regulated by phosphorylation. Proc Natl Acad Sci U S A (2008) 1.00
Epigenetic regulation of the X-linked tumour suppressors BEX1 and LDOC1 in oral squamous cell carcinoma. J Pathol (2013) 1.00
In vitro and in vivo studies of a novel potential anticancer agent of isochaihulactone on human lung cancer A549 cells. Biochem Pharmacol (2006) 0.98
Aurora kinase inhibitor patents and agents in clinical testing: an update (2009-10). Expert Opin Ther Pat (2011) 0.96
A novel oral indoline-sulfonamide agent, N-[1-(4-methoxybenzenesulfonyl)-2,3-dihydro-1H-indol-7-yl]-isonicotinamide (J30), exhibits potent activity against human cancer cells in vitro and in vivo through the disruption of microtubule. J Pharmacol Exp Ther (2007) 0.93
Reciprocal regulation of microRNA-99a and insulin-like growth factor I receptor signaling in oral squamous cell carcinoma cells. Mol Cancer (2014) 0.93
Targeting cathepsin S induces tumor cell autophagy via the EGFR-ERK signaling pathway. Cancer Lett (2011) 0.93
Investigating the association between oral hygiene and head and neck cancer. Oral Oncol (2013) 0.92
Novel mutation of topoisomerase I in rendering cells resistant to camptothecin. Cancer Res (2002) 0.92
Chamaecypanone C, a novel skeleton microtubule inhibitor, with anticancer activity by trigger caspase 8-Fas/FasL dependent apoptotic pathway in human cancer cells. Biochem Pharmacol (2009) 0.92
Autophagy induced by cathepsin S inhibition induces early ROS production, oxidative DNA damage, and cell death via xanthine oxidase. Free Radic Biol Med (2013) 0.92
A phase I study of weekly docetaxel, 24-hour infusion of high-dose fluorouracil/leucovorin and cisplatin in patients with advanced gastric cancer. Oncology (2002) 0.90
Microtubule-associated histone deacetylase 6 supports the calcium store sensor STIM1 in mediating malignant cell behaviors. Cancer Res (2013) 0.89
Phase II study of gemcitabine plus vinorelbine in the treatment of cisplatin-resistant nasopharyngeal carcinoma. Head Neck (2006) 0.89
4- and 5-aroylindoles as novel classes of potent antitubulin agents. J Med Chem (2007) 0.88
Arecoline arrests cells at prometaphase by deregulating mitotic spindle assembly and spindle assembly checkpoint: implication for carcinogenesis. Oral Oncol (2010) 0.88
Phase I and pharmacokinetic study of oral thalidomide in patients with advanced hepatocellular carcinoma. Cancer Chemother Pharmacol (2006) 0.88
Caffeic acid phenethyl ester suppresses proliferation and survival of TW2.6 human oral cancer cells via inhibition of Akt signaling. Int J Mol Sci (2013) 0.88
Combination of arsenic trioxide and BCNU synergistically triggers redox-mediated autophagic cell death in human solid tumors. Free Radic Biol Med (2011) 0.87
Mechanical regulation of cancer cell apoptosis and autophagy: roles of bone morphogenetic protein receptor, Smad1/5, and p38 MAPK. Biochim Biophys Acta (2013) 0.87
5-Amino-2-aroylquinolines as highly potent tubulin polymerization inhibitors. J Med Chem (2010) 0.86
Discovery of 4-amino and 4-hydroxy-1-aroylindoles as potent tubulin polymerization inhibitors. J Med Chem (2008) 0.86
Cholestane-3β, 5α, 6β-triol suppresses proliferation, migration, and invasion of human prostate cancer cells. PLoS One (2013) 0.85
Four new 6-nor5(6-->7)abeo-abietane type diterpenes and antitumoral cytotoxic diterpene constituents from the bark of Taiwania cryptomerioides. Planta Med (2005) 0.85
Cancer cells acquire mitotic drug resistance properties through beta I-tubulin mutations and alterations in the expression of beta-tubulin isotypes. PLoS One (2010) 0.85
Induction chemotherapy with gemcitabine, oxaliplatin, and 5-fluorouracil/leucovorin followed by concomitant chemoradiotherapy in patients with locally advanced pancreatic cancer: a Taiwan cooperative oncology group phase II study. Int J Radiat Oncol Biol Phys (2011) 0.85
Synthesis and biological evaluation of 1-(4'-Indolyl and 6'-Quinolinyl) indoles as a new class of potent anticancer agents. Eur J Med Chem (2011) 0.85
MBP-1 is efficiently encoded by an alternative transcript of the ENO1 gene but post-translationally regulated by proteasome-dependent protein turnover. FEBS J (2010) 0.84
Synthesis and evaluation of 3-aroylindoles as anticancer agents: metabolite approach. J Med Chem (2009) 0.84
Downregulation of a putative tumor suppressor BMP4 by SOX2 promotes growth of lung squamous cell carcinoma. Int J Cancer (2014) 0.84
[Application of neurally adjusted ventilatory assist in infants who underwent cardiac surgery for congenital heart disease]. Zhongguo Dang Dai Er Ke Za Zhi (2009) 0.84
Allergies and risk of head and neck cancer: an original study plus meta-analysis. PLoS One (2013) 0.84
Design and synthesis of alpha-ketoamides as cathepsin S inhibitors with potential applications against tumor invasion and angiogenesis. J Med Chem (2010) 0.83
Tamoxifen accelerates proteasomal degradation of O6-methylguanine DNA methyltransferase in human cancer cells. Int J Cancer (2007) 0.83
2,2'-Diphenyl-1-picrylhydrazyl radical-scavenging active components from adlay (Coix lachryma-jobi L. var. ma-yuen Stapf) hulls. J Agric Food Chem (2002) 0.83
Concise syntheses of N-aryl-5,6,7-trimethoxyindoles as antimitotic and vascular disrupting agents: application of the copper-mediated Ullmann-type arylation. Org Biomol Chem (2011) 0.83
Gelsolin regulates cisplatin sensitivity in human head-and-neck cancer. Int J Cancer (2014) 0.83
Three new oleanane-type triterpenes from Ludwigia octovalvis with cytotoxic activity against two human cancer cell lines. J Nat Prod (2004) 0.83
Antitumor activities and pharmacokinetics of silatecans DB-67 and DB-91. Pharmacol Res (2009) 0.82
MPT0B098, a novel microtubule inhibitor that destabilizes the hypoxia-inducible factor-1α mRNA through decreasing nuclear-cytoplasmic translocation of RNA-binding protein HuR. Mol Cancer Ther (2013) 0.82
Modulation of chemotactic and pro-inflammatory activities of endothelial progenitor cells by hepatocellular carcinoma. Cell Signal (2011) 0.82
The interplay between alcohol consumption, oral hygiene, ALDH2 and ADH1B in the risk of head and neck cancer. Int J Cancer (2014) 0.81
Azaindolylsulfonamides, with a more selective inhibitory effect on histone deacetylase 6 activity, exhibit antitumor activity in colorectal cancer HCT116 cells. J Med Chem (2014) 0.81
Structure-activity and crystallographic analysis of benzophenone derivatives-the potential anticancer agents. Bioorg Med Chem Lett (2003) 0.81
Antitumor AHMA linked to DNA minor groove binding agents: synthesis and biological evaluation. J Med Chem (2002) 0.81
A novel synthetic microtubule inhibitor, MPT0B214 exhibits antitumor activity in human tumor cells through mitochondria-dependent intrinsic pathway. PLoS One (2013) 0.81
Alpha-fetoprotein response in advanced hepatocellular carcinoma receiving cytostatic agent. J Clin Oncol (2009) 0.81
Transcriptional repression of O6-methylguanine DNA methyltransferase gene rendering cells hypersensitive to N,N'-bis(2-chloroethyl)-N-nitrosurea in camptothecin-resistant cells. Mol Pharmacol (2008) 0.81
Gene expression profiling for analysis acquired oxaliplatin resistant factors in human gastric carcinoma TSGH-S3 cells: the role of IL-6 signaling and Nrf2/AKR1C axis identification. Biochem Pharmacol (2013) 0.81
Mitochondria-mediated and p53-associated apoptosis induced in human cancer cells by a novel selenophene derivative, D-501036. Biochem Pharmacol (2006) 0.80
Advances in Aurora kinase inhibitor patents. Expert Opin Ther Pat (2009) 0.80
Generation of ligand-based pharmacophore model and virtual screening for identification of novel tubulin inhibitors with potent anticancer activity. J Med Chem (2009) 0.80
Arterial switch operation with coronary arteries from a single sinus in infants. J Card Surg (2008) 0.80
BPR1K653, a novel Aurora kinase inhibitor, exhibits potent anti-proliferative activity in MDR1 (P-gp170)-mediated multidrug-resistant cancer cells. PLoS One (2011) 0.80
5-Amino-2-aroylquinolines as highly potent tubulin polymerization inhibitors. Part 2. The impact of bridging groups at position C-2. J Med Chem (2011) 0.80
Scaffold-hopping strategy: synthesis and biological evaluation of 5,6-fused bicyclic heteroaromatics to identify orally bioavailable anticancer agents. J Med Chem (2011) 0.80
D-501036, a novel selenophene-based triheterocycle derivative, exhibits potent in vitro and in vivo antitumoral activity which involves DNA damage and ataxia telangiectasia-mutated nuclear protein kinase activation. Mol Cancer Ther (2007) 0.80
Antimutagenic constituents of adlay (Coix lachryma-jobi L. var. ma-yuen Stapf) with potential cancer chemopreventive activity. J Agric Food Chem (2011) 0.79
A novel peroxisome proliferator-activated receptor alpha/gamma agonist, BPR1H0101, inhibits topoisomerase II catalytic activity in human cancer cells. Anticancer Drugs (2008) 0.79
Activation of PPAR-α induces cell cycle arrest and inhibits transforming growth factor-β1 induction of smooth muscle cell phenotype in 10T1/2 mesenchymal cells. Cell Signal (2013) 0.79
Structure-activity relationship studies of 3-aroylindoles as potent antimitotic agents. ChemMedChem (2006) 0.79
Arginine deprivation as a new treatment strategy for head and neck cancer. Oral Oncol (2012) 0.79
Cytotoxic C(35) terpenoid cryptotrione from the bark of Cryptomeria japonica. Org Lett (2010) 0.78
CDKN1A-mediated responsiveness of MLL-AF4-positive acute lymphoblastic leukemia to Aurora kinase-A inhibitors. Int J Cancer (2014) 0.78
Phase I study of biweekly gemcitabine followed by oxaliplatin and simplified 48-h infusion of fluorouracil/leucovorin for advanced pancreatic cancer. J Gastroenterol Hepatol (2006) 0.78
MPT0B169, a new tubulin inhibitor, inhibits cell growth and induces G2/M arrest in nonresistant and paclitaxel-resistant cancer cells. Pharmacology (2013) 0.78
A novel bis-benzylidenecyclopentanone derivative, BPR0Y007, inducing a rapid caspase activation involving upregulation of Fas (CD95/APO-1) and wild-type p53 in human oral epidermoid carcinoma cells. Biochem Pharmacol (2004) 0.78
Synthesis and structure-activity relationships of 1-benzyl-4,5,6-trimethoxyindoles as a novel class of potent antimitotic agents. ChemMedChem (2009) 0.78
Synthesis and structure-activity relationships of 3-aminobenzophenones as antimitotic agents. J Med Chem (2004) 0.78
C35 terpenoids from the bark of Calocedrus macrolepis var. formosana with activity against human cancer cell lines. J Nat Prod (2006) 0.77
Dual inhibition of topoisomerase I and tubulin polymerization by BPR0Y007, a novel cytotoxic agent. Biochem Pharmacol (2003) 0.77
[Outcome of oral bosentan in children with congenital heart disease associated pulmonary arterial hypertension]. Zhonghua Yi Xue Za Zhi (2009) 0.77
BPR0C261 is a novel orally active antitumor agent with antimitotic and anti-angiogenic activities. Cancer Sci (2010) 0.76
Dissecting the EGFR-PI3K-AKT pathway in oral cancer highlights the role of the EGFR variant III and its clinical relevance. J Biomed Sci (2013) 0.76
Paclitaxel and carboplatin-induced complete remission in peritoneal carcinomatosis of unknown origin: a report of two cases and review of the literature. Tumori (2010) 0.76
Enhancement of non-homologous end joining DNA repair capacity confers cancer cells resistance to the novel selenophene compound, D-501036. Cancer Lett (2011) 0.76
Differences in the frequencies of K-ras c12-13 genotypes by gender and pathologic phenotypes in colorectal tumors measured using the allele discrimination method. Environ Mol Mutagen (2011) 0.76
Multi-slice computed tomography assessment of bronchial compression with absent pulmonary valve. Pediatr Radiol (2014) 0.75
Furanylazaindoles: potent anticancer agents in vitro and in vivo. J Med Chem (2013) 0.75
Targeted Casp8AP2 methylation increases drug resistance in mesenchymal stem cells and cancer cells. Biochem Biophys Res Commun (2012) 0.75
Alcohol Drinking Obliterates the Inverse Association Between Serum Retinol and Risk of Head and Neck Cancer. Medicine (Baltimore) (2015) 0.75
2-amino-3,4,5-trimethoxybenzophenones as potent tubulin polymerization inhibitors. ChemMedChem (2011) 0.75
Synthesis and biological evaluation of 4-aroyl-6,7,8-trimethoxyquinolines as a novel class of anticancer agents. Molecules (2011) 0.75
Synthesis and structure-activity relationships of 2-amino-1-aroylnaphthalene and 2-hydroxy-1-aroylnaphthalenes as potent antitubulin agents. J Med Chem (2008) 0.75